Next-Microbiome is a leading research and development company committed to revolutionizing gut health through innovative probiotic solutions. Founded by renowned microbiologist Ali Rıza Akın, with over 25 years of experience in human microbiota research, we develop cutting-edge products designed to support and enhance the gut microbiota, promoting overall health and well-being.
Ali Rıza Akın, a distinguished microbiologist with over 25 years of experience, began his scientific career in Northern California's Silicon Valley, focusing on human microbiota, next-generation probiotics, and host-microbe relationships. Over the past decade, he has led the team that first discovered dozens of next-generation bacteria worldwide.
Akın's extensive knowledge and expertise have been instrumental in guiding Next-Microbiome's mission to develop new-generation probiotics. He is one of the authors of the book 'Bacterial Therapy of Cancer' alongside the world's leading scientists.
His research has been conducted in collaboration with prestigious institutions including UCLA, Imperial College of London, University of Manchester, University of Groningen, University College Cork, the Bill and Melinda Gates Foundation, and Novartis Biomedical Research Institute. With patents registered in Europe, Japan, and the United States, he has also filed applications for 'Treatment of Metabolic Diseases with Next-Generation Bacteria'.
Akın has developed systems focused on Akkermansia and Christensenella, the most renowned next-generation probiotics, and has pioneered high-efficacy products for appetite control, insulin resistance elimination, weight loss, stress-depression elimination, and menstrual pain relief. These products were first launched in Turkey and became available through private health insurance in the United States in 2022.
His latest project involves working with hundreds of next-generation probiotic strains within a single product concept, planning to end fecal transplantation worldwide. Through his Anaerobic Microbiology research, Ali Rıza Akın continues to open new horizons for human health in the 21st century.
Collaborated with world's leading scientists on this groundbreaking publication
Led the team that first discovered dozens of next-generation bacteria worldwide
Developed first-of-their-kind products for appetite control, insulin resistance, and metabolic health
Worked with UCLA, Imperial College, Gates Foundation, Novartis, and leading universities
Developed systems focused on the most renowned next-generation probiotics
Developed and launched the world's first high-efficacy products combining Akkermansia and Christensenella with next-generation prebiotics in Turkey.
Products developed by Ali R. Akın were made available through private health insurance in the United States in 2022.
Working on a project involving hundreds of next-generation probiotic strains, planning to end fecal transplantation worldwide.
Our workflow strategy ensures a seamless process from concept to execution. We focus on efficiency, creativity, and precision to deliver outstanding results for every project.
We begin by brainstorming and refining creative ideas that align with your brand vision. This phase sets the foundation for a strategic and impactful execution.
A well-defined roadmap ensures smooth project execution. We focus on research, goal-setting, and structuring a clear strategy tailored to your objectives.
Bringing ideas to life with precision and creativity. Our team works on design, development, and content creation while ensuring quality and consistency.
We analyze results, gather feedback, and make refinements to enhance performance. Continuous improvement ensures long-term success and effectiveness.
Embracing creativity and new ideas to drive progress.
Working together to achieve collective success.
Acting with honesty and transparency in all we do.
Striving for the highest quality in everything we create.
Putting our clients' needs and satisfaction at the forefront.
Staying flexible and responsive to change and new challenges.
We believe that 'Healthy Microbiota, Healthy Human' is the foundation of well-being. Our mission is to make this goodness accessible to more people, starting from the goodness that begins with breast milk.
We understand that the microbiota is vital for our health. Maintaining a healthy microbiota creates a state of overall 'goodness' that spreads throughout the body, starting from our intestines. At Next-Microbiome, we call this 'Goodness from Within' and focus all our work on multiplying this goodness.
In all our holistic microbiota support products, we combine next-generation probiotics like Akkermansia muciniphila with traditional probiotics like Bifidobacterium to increase diversity. We carefully ensure that probiotics work in harmony in each product, supporting our formulations with prebiotics that probiotics need to feed on, and ancient plants that humanity has used for tens of thousands of years.
Founded in Silicon Valley, Northern California, USA, our core research area is human microbiota and next-generation probiotic bacteria. We work at the heart of science and innovation, with a mission to contribute to a healthy future. We work to better understand the human microbiota, develop pioneering products in this field, and share the key to a healthy life with wider audiences.
At Next-Microbiome, we combine scientific rigor with innovative thinking to develop products that harness the power of beneficial bacteria for human health.
A comprehensive collection of groundbreaking patents and influential research publications that showcase our commitment to advancing microbiome science.
Ali Rıza Akın's research has focused significantly on Akkermansia bacteria, a unique microbe that plays a vital role in maintaining gut health. Akkermansia is known for its ability to strengthen the gut barrier, reduce inflammation, and improve metabolic health.
Akkermansia muciniphila, discovered nearly 20 years ago at Wageningen University, has been proven through countless studies to have miraculous effects on human health. While Bifidobacterium family members provide 1 unit of protection against cancer, Akkermansia family members protect individuals dozens of times more and simultaneously fight cancer by activating the body's defense system.
Akkermansia helps maintain the integrity of the gut lining, protecting against harmful substances.
This beneficial bacterium plays a crucial role in modulating inflammatory responses in the body.
Research shows Akkermansia supports healthy metabolism and insulin sensitivity.
By supporting gut health, Akkermansia contributes to overall immune system function.
We are proud to collaborate with leading research institutions and organizations worldwide to advance microbiome science and develop innovative probiotic solutions.
I'm your AI assistant for Next Microbiome. Ask me anything about our products, gut health, or Akkermansia muciniphila.
